Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Let's talk about 5% of procedures being handled today in the medical room by robotics and let's talk about the 95% that are not
600 million shares is peanuts when you think about for the Googles os, Johnson & Johnson's os, etc
I'm not saying we're going to be the apple of robotics surgery but I
Am saying we have a zero debt and not afraid at our opportunity nor 600 million shares os
Happy to report my original tip to Titan 4 years ago at Olympus Medical is in Titan until the end. He works upstate NY and let me know that the surgeons and administrators at a many hospitals are DONE with intuitive reps and the product.
Specifically referring to the type of hospital that doesn't do a high case load of procedures per week/month. he referenced Community General in Syracuse that had the arms of the da Vinci knock out 20 k of Medical lights and at the same time the arm dismantled from the device at pre op and not only prevented the procedures for that day but billed another 150 k to the hospital to boot.
Community Generals immediate need have been ignored by the intuitive rep that covers the territory of a Rochester based hospital that will do ten fold the amount of procedures with the same tech
This is the TITAN story, NO RS ST, NO SHORTING, STAY LONG STAY STRONG
Our story:
Ontario welcomes JLABS
JLABS @ Toronto
MaRS Centre, West Tower
661 University Avenue, Suite 1300
Toronto, Ontario, Canada
M5G 0B7
647-243-5200
As the first JLABS to open outside the United States, JLABS @ Toronto joins a network of life science facilities that are based throughout the United States in San Diego (the flagship JLABS), San Francisco, Boston and Houston.
These facilities are home to over 140 early-stage companies advancing pharmaceutical, medical device, consumer and digital health programs. JLABS @ Toronto is located on the 13th floor in the MaRS West Tower and is a collaboration among Johnson & Johnson Innovation, The University of Toronto, MaRS Discovery District, Janssen Inc., MaRS Innovation, and the Government of Ontario. JLABS @ Toronto opened on May 11th, 2016, the 40,000-square foot facility includes cutting-edge, modular and scalable lab space, state-of-the-art equipment, with access to scientific, industry and capital funding experts.
The space also features JLABS' inaugural device and digital prototype lab that provides entrepreneurs with access to highly specialized tools and skills building programs to design and develop smart health technologies.
JNJ Innovation Toronto Labs around
The corner a few blocks??
Http://jlabs.jnjinnovation.com/locations/jlabs-toronto
https://maps.google.com/maps?oe=UTF-8&hl=en-us&client=safari&um=1&ie=UTF-8&fb=1&gl=us&entry=s&sa=X&ftid=0x882b34b7d77de623:0x9b960e67d67a9351&gmm=CgIgAQ%3D%3D
Per the site floor 10 suite 1000 is available immediately,
http://www.adgarcanada.com/portfolio/view-properties/170-university-avenue#
TITXF - OTCQB Certification
http://www.otcmarkets.com/financialReportViewer?symbol=TITXF&id=170712
Key take away is really about the data, content is googles king! Other key take awayz democratize robotic surgery to areas underserved by financial restriction.
It's been said b4 and I will say it again Fowler is Dad and Scott H is his son, it's like the verb CEO has been reading from the book of Titan medical since Fowler started preaching our gospel
Adrock are you shorting this stock?
Thanks again fly for your contributions
Cheers to all the great contributions on this board grow up to all the nay sayers
Sell sell sell were going to .0001, blah blah blah cuin go pump ecig
Is it plausible trxc mergers with titxf - not in favor personally
Question to all the shorts is who cares about ur pessimistic view
Your prolly spot on, let's hope it's the one patent McRally referenced earlier this year that had conflicting findings
Huh? How do u explain this?
Can we please get back to the connections that i clearly missed, this is why I drink the koolaid and have 13 of my closest family and friends in this same stock we all few on this board feel passionate about, knowledge is power, please do empower a fellow Titan shareholder Brudder
Woah woah back up the horses, I'm drinking the koolaid, hence my 35k in the hole but I want to point out "me 2 hash tag R Boy McNally" means i don't hate I appreciate
According to JUrology everyone has an agenda, and you clearly have a conviction for R Boy McNally, me 2 Hashtag R Boy McNally
I've got a long journey to .73 upside down smiley face hashtag let's rally McNally
"We still need to raise additional funding of approximately $70 million to meet the 2018 filing objective. However, we believe with the multi-billion dollar opportunity ahead of us, sufficient financing and successful execution by our team, we can create substantial shareholder value.” R Boy McNally, LETS RALLY
Question to the board
Let's just say I'm a bigTime Healthcare conglomerate with interest in robotics
I initially become investor x in Titan, and I have been investing the over allotment of x shares per each round of finance.....
What if... X investor has been same x investor since beginning of each round of finance....
And as the shares per price lower x investor gains more equity per round of finance
To the point of x investor takes majority shareholder
Is it possible this investor turn majority shareholder takes new direction of Titan ?????
What's the philosophy behind the Morningstar Rating for stocks?
Morningstar has been analyzing investment strategies for nearly 20 years. We've become experts at separating styles that haven't worked from those that have. And we've also developed our own strategy for investing in stocks.
It's pretty simple. Buying a stock means becoming part owner in a business, which means that over the long run, stock prices are ultimately driven by corporate financial performance. Therefore, stocks should be valued as pieces of a business--not as, in the words of Warren Buffett, "little wiggling things with charts attached." That's why we spend a great deal of time thinking about things such as competitive advantages, cash flows, and economic moats--all of which are crucial to valuing companies as businesses.
It's no surprise, then, that the Morningstar Rating for stocks takes a business-centered approach. The rating compares a stock's current price with our estimate of the stock's fair value. We base this estimate on the present value of the company's future cash flows. Not on stock-price momentum. Nor on investor sentiment. Nor on other nonfinancial factors.
How is the rating created?
Morningstar analysts estimate a company's future financial performance using a detailed discounted cash-flow model that factors in projections for the company's income statement, balance sheet, and cash-flow statement. The result is an analyst-driven estimate of the stock's fair value?
What determines whether a stock gets 1, 2, 3, 4, or 5 stars?
The Morningstar Rating for stocks system identifies stocks trading at a discount or premium to our estimate of their fair values. Generally speaking, stocks trading at large discounts to our analysts' fair value estimates will receive higher (4 or 5) star ratings, and stocks trading at large premiums to their fair value estimates will receive lower (1 or 2) star ratings. Stocks that are trading very close to our analysts' fair value estimates will receive 3-star ratings.
A stock's star rating is driven by its level of expected return. For example, 3-star stocks are those that should offer a "fair return," one that compensates for the riskiness of the stock. Five-star stocks, of course, should offer an investor a return that's well above the company's cost of equity, and high-risk 5-star stocks should offer a better expected return than low-risk 5-star stocks.
The riskier the stock, the greater the discount needed to earn 5 stars or premium needed to hit 1 star. The chart below shows the price/fair value ratios that correspond to each rating band.
On August 19, 2004, Google went public with a price of $85 for its roughly 19.6 million shares
AND THE REST IS 80% IP HISTORY
Funny how sound Titan patent protection prevents any such class action thinking
so we have no debt on the books just diluted pps through shelf offerings.
Our offerings have been bought up very quickly
And let's say an entity that bought the offering was a JJDC or Google ventures.
Then if this is bought out by a Verb surgical it is almost like they are paying themselves.
Just a theory to think about. I am not personally worried about it.
I think we have to get to a certain milestone and the Kat will be out of the bag.
POSTED By Katalyst89, just regurgitating so the gloom and dooms have something to think about when cleaning out there cats litterboxes and eating ramen noodles
MAD PROPS TO TITAN IP and JUrology, love a member of the community that offers great finds and positive feedback as opposed to the many gloom and doom woah is me posters
RockoTaco I don't see verb as their client http://www.lhai.com/about-us/clients/current-clients
Curtis needs to update his LinkedIn profile
What verb and Scott H is after is the moonshot idea of democrasizing the most advanced procedures in medical science to the 95 percent of the market that needs it the most.
Verb understands you can't accomplish the marathon without taking the first step.
The end game for google, verb, will and will always start and finish with CONTENT. They want the data, and will offer the most advanced software at no cost to simply gain the most important asset in any Industry, the data.
They take this and reinvent a wheel so bad ass they change and revolutionize the most advanced procedures in medical science
With that said, DR FOWLER has been speaking this tongue light years before a partnership with the worlds largest company and Johnson n Johnson.
We are in good hands, we took the industry and questioned its barriers, verb is getting all the credit but we preached it since our inception
Huh? A greenshoe is a clause contained in the underwriting agreement of an initial public offering (IPO) that allows underwriters to buy up to an additional 15% of company shares at the offering price.
Agreed McNallys t's are crossed and i's dotted, The interesting and most important aspect of this non-revenue producing company is intellectual property he did mention out of the 14 patents and 30 pending, The in-house and external world renowned patent attorneys hired by Titan have only found one conflicting patent. It would be interesting to find which that Patent is and who the party that conflicts
Ok found it under overview section in investors
Thank iitf, where is the webcast link?? I have tried every tab under investors and can't seem to find it
Trying to replay the call with no avail
Dialing 888-203-1112, punching in 5784933# then it asks for the pin, anyone know what the pin # is??
Trying to replay the call with no avail
Dialing 888-203-1112, punching in 5784933# then it asks for the pin, anyone know what the pin # is??
How about a grant from the army for 70 million to take Titan to the promise land
Come ON Hargrove
https://www.army.mil/article/184404/new_civilian_aides_to_the_secretary_of_the_army_invested
Disclosures
Company Role Financial Date Disclosed
Surgical Specialties Consultant or Advisor Yes 03/03/2017
Surgiquest Consultant or Advisor No 09/02/2015
Mimedx Consultant or Advisor Yes 01/07/2016
GenomeDx Consultant or Advisor No 09/02/2015
Ethicon Consultant or Advisor Yes 01/07/2016
Teleflex Consultant or Advisor Yes 03/03/2017
Titan Consultant or Advisor Yes 03/03/2017
Contact Us
AUA University
Vipul R. Patel, MD
Dr. Vipul Patel currently serves as the medical director of the urologic oncology program for the Florida Hospital Cancer Institute. He holds an appointment at the University of Central Florida School of Medicine as Professor of Urology. He also has honorary titles as Professor at the Russian Academy of Sciences, at the University of Milan and the University of Korea School Of Medicine. Dr. Patel attended medical school at Baylor College of Medicine, and did both his residency and fellowship training at the University of Miami. Prior to moving to Florida, he was Director of Robotic and Minimally Invasive Urologic Surgery at the Ohio State University.
Dr Patel specializes in the field of urologic oncology and has performed over 8500 robotic radical prostatectomies. In addition to his clinical duties, Dr. Patel has basic science collaborations with the Sanford-Burnham Institute and the University of Central Florida studying mRNA and its relation to prostate cancer. He recently received a $4.2 million grant from the United States Department of Defense for research in telesurgery and simulation. Yearly, Dr Patel trains hundreds of surgeons how to safely adopt minimally invasive surgery into their surgical practices. He leads the resident course for the SESAUA whereby residents from the SES are able to get a free two-day hands-on course in robotic surgery.
Dr. Patel is best known for his work in the field of robotic surgery, which he has now practiced for over a decade. He is the founder of the Society of Robotic Surgery, a multi-specialty organization responsible for education and training. He is also Editor Emeritus of the Journal of Robotic Surgery and has authored the first textbook on robotics in urology.
Dr. Patel’s passion for helping men with prostate cancer and his ability in philanthropy has led him to create the International Prostate Cancer Foundation, a not-for-profit charitable organization dedicated to the eradication of prostate cancer. The foundation has raised millions of dollars to support men with prostate cancer. Currently, he is pioneering a campaign for education on PSA screening in men.
Academically, Dr. Patel serves as a mentor to medical students, residents and fellows. He has authored 4 textbooks and has contributed his knowledge to many others. He has 95 peer-reviewed publications. He has lectured internationally as an invited speaker at over 100 meetings.
In his decade in practice, his goal has remained singular: to help men in their battle against prostate cancer and the physicians that will need to take care of them.
Disclosures
Company Role Financial Date Disclosed
Surgical Specialties Consultant or Advisor Yes 03/03/2017
Surgiquest Consultant or Advisor No 09/02/2015
Mimedx Consultant or Advisor Yes 01/07/2016
GenomeDx Consultant or Advisor No 09/02/2015
Ethicon Consultant or Advisor Yes 01/07/2016
Teleflex Consultant or Advisor Yes 03/03/2017
Titan Consultant or Advisor Yes 03/03/2017
Contact Us
American Urological Association
1000 Corporate Boulevard
Linthicum, MD 21090
toll free (US Only): 866.RING.AUA (866.746.4282)
phone: 410.689.3700
fax: 410.689.3800
Follow Us
Office of Education
phone: 410.689.3930
email: education@auanet.org
Upcoming Courses
Urology Update 2017: For Primary Care and Advanced Practice Providers
Boston, MA
MAY 13, 2017
Annual Review Course 2017
San Antonio, TX
JUNE 9-11, 2017
Fundamentals in Urology
Charlottesville, VA
JUNE 16-20, 2017
© 2017 AMERICAN UROLOGICAL ASSOCIATION. ALL RIGHTS RESERVED.
back to top
Hoping this is verb
The creation and refinement of software for production system functionality has not yet commenced. The Company plans to commence this process in the first half of 2017, and it will likely remain an intensive, ongoing process through the remainder of the year.